Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 219

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 219
---
 |   2.25 | ​ |                ​ | ​ | ​           | ​ |
| Warrants expired in 2023                 | ​ |               -278 | ​ | ​                | -16.00 | ​ |                ​ | ​ | ​           | ​ |
| Warrants outstanding - December 31, 2023 |   |          8,203,839 | ​ | $                |  14.93 | ​ |              4.3 | ​ | $           | — |

F-22

#### 13)    Dilutive convertible securitiesThe following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net loss per share because their inclusion would have been antidilutive:​​​​​​​​For the Years Ended​​December 31,​20232022Stock options509,13359,067RSUs​—​40,238Series A Convertible Preferred stock​5,985,519​—Warrants8,203,8391,004,115Total14,698,4911,103,420​​14)   Marketing, Licensing and Distribution Agreements(a)    VivusOn September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70million. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction.Under the License Agreement, the Company will pay MTPC a royalty of5% on the first $500million of net sales and6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end